SWITCH SWEDEHEART Trial: Prasugrel Matches Ticagrelor with Less Bleeding
According to results presented at the ESC Congress and published in the New England Journal of Medicine, prasugrel reduced major cardiovascular events to the same extent as ticagrelor while lowering major bleeding risks after coronary stenting in patients with acute coronary syndromes. The registry-based SWITCH SWEDEHEART trial evaluated 17,095 consecutive adults undergoing percutaneous coronary intervention … Read more